Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. [electronic resource]
Producer: 20180322Description: 68833-68841 p. digitalISSN:- 1949-2553
- Adenine -- analogs & derivatives
- Agammaglobulinaemia Tyrosine Kinase
- Antineoplastic Agents -- therapeutic use
- Cell Transformation, Neoplastic
- DNA Mutational Analysis
- Drug Resistance, Neoplasm
- Female
- High-Throughput Nucleotide Sequencing
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Middle Aged
- Mutation
- Neoplasm Recurrence, Local
- Piperidines
- Protein Kinase Inhibitors -- therapeutic use
- Protein-Tyrosine Kinases -- genetics
- Pyrazoles -- therapeutic use
- Pyrimidines -- therapeutic use
- src Homology Domains
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.